STAAR Surgical (NASDAQ:STAA) Earns “Equal Weight” Rating from Stephens

STAAR Surgical (NASDAQ:STAA)‘s stock had its “equal weight” rating reiterated by investment analysts at Stephens in a report issued on Tuesday,Benzinga reports. They presently have a $17.00 price target on the medical instruments supplier’s stock. Stephens’ price target suggests a potential downside of 3.18% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. StockNews.com downgraded shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus decreased their target price on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Mizuho downgraded STAAR Surgical from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group reduced their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $25.29.

STAAR Surgical Stock Down 0.3 %

Shares of NASDAQ STAA opened at $17.56 on Tuesday. The firm’s 50-day moving average price is $20.29 and its 200-day moving average price is $26.02. The company has a market cap of $866.10 million, a PE ratio of -42.83 and a beta of 0.66. STAAR Surgical has a 52-week low of $13.50 and a 52-week high of $52.68.

Insider Activity

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 23,000 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was acquired at an average price of $24.33 per share, for a total transaction of $559,590.00. Following the completion of the transaction, the insider now directly owns 10,848,631 shares of the company’s stock, valued at approximately $263,947,192.23. This represents a 0.21 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have purchased 857,343 shares of company stock valued at $14,213,132. 1.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On STAAR Surgical

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of STAAR Surgical by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after acquiring an additional 31,212 shares during the period. HighTower Advisors LLC bought a new stake in STAAR Surgical during the third quarter valued at about $336,000. Polar Asset Management Partners Inc. grew its stake in STAAR Surgical by 44.3% in the third quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock valued at $6,271,000 after purchasing an additional 51,800 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after purchasing an additional 172,779 shares in the last quarter. Finally, Defender Capital LLC. raised its holdings in STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock worth $17,041,000 after purchasing an additional 23,950 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.